RxDoctor Payments DataLook up a doctor →

Sahil Bakshi, DO

Cardiovascular Disease · Plano, TXNPI 1659368199

Payments from drug & device makers

$627,925in general payments, 2019–2025

Across 826 payments — averaging $760.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$343K
  • Actelion Pharmaceuticals US, Inc.$109K
  • Bayer$70K
  • Actelion Pharmaceuticals, Ltd$70K
  • United Therapeutics Corporation$28K
  • Novartis$2K
  • plus $6K from 37 others

What the payments were for

  • Consulting fees$2220%
  • Speaking & faculty fees$146,27487%
  • Travel & lodging$6,2744%
  • Food & beverage$14,3829%
  • Education$250%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$627,925 in reported general payments places this provider in the 95th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$596,295
Medicare patients
2,349
Services billed
11,676

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpsumitMacitentan176$2,181,785
UptraviSelexipag55$1,349,449
AdempasRiociguat42$545,818
Tyvaso DpiTreprostinil17$401,594
EliquisApixaban255$329,229
OpsynviMacitentan/Tadalafil13$167,655
Repatha SureclickEvolocumab165$145,995
Orenitram ErTreprostinil Diolamine31$74,595
XareltoRivaroxaban58$68,038
Tadalafil92$44,248
EntrestoSacubitril/Valsartan38$43,650
BrilintaTicagrelor15$17,264
FarxigaDapagliflozin Propanediol26$14,120
VascepaIcosapent Ethyl13$11,513
Sildenafil Citrate51$6,512

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi, Opsynvi$108,915$3,698,889244 claims
BayerAdempas$70,279$545,81842 claims
PfizerEliquis$153$329,229255 claims
Johnson & JohnsonXarelto$382$68,03858 claims
NovartisEntresto$1,926$43,65038 claims
AstraZenecaBrilinta, Farxiga$158$31,38541 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Plano

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →